Abstract The incretins glucose-dependent insulinotropic polypeptide (GIP) and glucagon-like peptide 1 (GLP-1) mediate insulin responses that are proportionate to nutrient intake to facilitate glucose tolerance 1
For weight concerns, a qualified doctor is the right place to start
During these visits, our doctors monitor side effects and overall tolerance to ensure the treatment remains safe and manageable
Cell 182 , 12321251.e1222 (2020)
Safety Comparison# Semaglutide# Well-characterized safety profile across thousands of patients: GI adverse events: 50-70% (mostly mild-moderate, dose-escalation related) Discontinuation due to AEs: ~7% (STEP 1) Boxed warning: Thyroid C-cell tumors (rodent data) Post-marketing signals: Pancreatitis, gallbladder events, ileus (rare) 8+ years of post-marketing surveillance Zovaglutide# Phase 2 safety data (303 patients, 24 weeks): GI adverse events: Present but low severity Discontinuation due to GI AEs: 1.3% (notably low for GLP-1 class) Monthly dosing showed fewer GI events than biweekly dosing No long-term safety data available No post-marketing experience The 1.3% GI-related discontinuation rate is notably lower than typical GLP-1 agonists (5-10%)
Sunscreens Mineral-based sunscreens with zinc oxide or titanium dioxide are less likely to irritate sensitive skin